Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 751.4% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $20.7 million (down 94.13% YoY), while the FY2025 annual figure was $13.7 million, down 96.13% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $7.9 million, up from $5.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $347.4 million in Q4 2024, with the low at -$13.5 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is $2.5 million (2023), against an average of $47.7 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities plunged 893.26% in 2022, then soared 751.4% in 2026.
• Syndax Pharmaceuticals' Cash from Financing Activities stood at $163.5 million in 2022, then surged by 58.09% to $258.5 million in 2023, then soared by 34.41% to $347.4 million in 2024, then plunged by 98.3% to $5.9 million in 2025, then jumped by 33.82% to $7.9 million in 2026.
• Business Quant data shows SNDX's Cash from Financing Activities at $7.9 million in Q1 2026, $5.9 million in Q4 2025, and $6.3 million in Q3 2025.